- Molecular NameTiclopidine
- SynonymTiclopidine HCL; Ticlopidine Hydrochloride
- Weight263.792
- Drugbank_IDDB00208
- ACS_NO55142-85-3
- Show 2D model
- LogP (experiment)3.46
- LogP (predicted, AB/LogP v2.0)3.9
- pka7.6
- LogD (pH=7, predicted)3.89
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-3.44
- LogSw (predicted, AB/LogsW2.0)0.07
- Sw (mg/ml) (predicted, ACD/Labs)0.04
- No.of HBond Donors0
- No.of HBond Acceptors1
- No.of Rotatable Bonds2
- TPSA31.48
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antiplatelet drug in the thienopyridine family.
- Absorption_value80.0
- Absorption (description)Absorption is greater than 80%. Food increases absorption.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding96.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMetabolized extensively by the liver; only trace amounts of intact drug are detected in the urine. At least 20 metabolites have been identified. It has been proposed that 1 or more active metabolites may account for ticlopidine's activity, because ticlopidine itself is an extremely weak platelet aggregation inhibitor in vitro at the concentrations achieved in vivo. However, no active metabolite has been identified.
- Half life7.9 h (in young volunteers) and 12.7 h (elderly) after a single dose; 91 h (young) and 98 h (elderly) after repeated dosing.
- ExcretionRenal and fecal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of acute toxicity were GI hemorrhage, convulsions, hypothermia, dyspnea, loss of equilibrium and abnormal gait.
- LD50 (rat)LD50=1600 mg/kg
- LD50 (mouse)LD50=500 mg/kg